Prime Medicine Stock
Prime Medicine operates as a biotechnology company.
Sign up today and learn more about Prime Medicine Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Prime Medicine Stock
Prime Medicine is a biotechnology company founded to deliver on the promise of Prime Editing, a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease.
Investors
ARCH Venture Partners
Grail, Prime Medicine, Aledade, Codiak Biosciences, Mindstrong, Metacrine, Beam Therapeutics
F-Prime Capital Partners
PharmEasy, Devoted Health, Benchling, SonderMind, Prime Medicine, Snapdocs, Flywire, Quartet, Caribou Biosciences, Unison Home Ownership Investors
Moore Strategic Ventures
Commonwealth Fusion, Scopely, Workrise, Group14 Technologies, Prime Medicine, Outdoorsy, La Haus, Autogrid
Osage University Partners
Samsara BioCapital
Funding History
| October 2019 | $115M |
|---|---|
| July 2021 | $200M |
Management
Board Member
Stephen Knight
Board Member
Robert Nelsen
Board Member
John Evans
Chief Scientific Officer
Jeremy Duffield
President & Chief Executive Office
Keith M. Gottesdiener
Board Member
Keith M. Gottesdiener
Board Member
David Schenkein
Co-founder
Andrew Anzalone
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
